X0508 4 2024-02-09 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001450485 Lurker Nancy C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 true true false false Executive Vice Chair false Common Stock 2024-02-09 4 M false 20000.00 0.00 A 155441.00 D Common Stock 2024-02-09 4 M false 17534.00 0.00 A 172975.00 D Common Stock 2024-02-09 4 F false 7962.00 28.80 D 165013.00 D Common Stock 2024-02-09 4 F false 6981.00 28.80 D 158032.00 D Common Stock 2024-02-13 4 G false 74681.00 0.00 D 83351.00 D Common Stock 2024-02-13 4 G false 74681.00 0.00 A 126889.00 I By Family Trust Restricted Stock Units 0.00 2024-02-09 4 M false 17534.00 0.00 D 2031-02-09 Common Stock 17534.00 0.00 D Restricted Stock Units 0.00 2024-02-09 4 M false 20000.00 0.00 D 2032-02-09 Common Stock 20000.00 20000.00 D Stock Option (Right to Buy) 12.90 2024-02-13 4 G false 3116.00 0.00 D 2030-02-28 Common Stock 3116.00 1558.00 D Stock Option (Right to Buy) 12.90 2024-02-13 4 G false 3116.00 0.00 A 2030-02-28 Common Stock 3116.00 73242.00 I By Family Trust Stock Option (Right to Buy) 13.13 2024-02-13 4 G false 4452.00 0.00 D 2031-02-09 Common Stock 4452.00 57878.00 D Stock Option (Right to Buy) 13.13 2024-02-13 4 G false 4452.00 0.00 A 2031-02-09 Common Stock 4452.00 155822.00 I By Family Trust Stock Option (Right to Buy) 10.13 2024-02-13 4 G false 5000.00 0.00 D 2032-02-09 Common Stock 5000.00 125000.00 D Stock Option (Right to Buy) 10.13 2024-02-13 4 G false 5000.00 0.00 A 2032-02-09 Common Stock 5000.00 115000.00 I By Family Trust No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units On February 13, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 28, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. /s/ Ron Honig, Attorney-in-Fact 2024-02-13